Strata Rx 2012: "The Convergence of Genomic and Phenomic Data", Alexis Borisy

Описание: Personalized medicine, leading to better and more efficient medicine for many, will advance substantially as datasets combining broad genomic and other molecular data are combined with phenomic data -- rich clinical parameter datasets containing information that clinical decision makers really want to know. Although much attention has been paid to the genomic data, the phenomic data is often the greater challenge. Now progress is being made on both fronts, and these genomic-phenomic datasets have the potential for tremendous innovation in Rx, Dx, and more. Where are these joined datasets emerging from first? What opportunities for innovation do they provide? What may this mean for the future of the personalized medicine ecosystem?

Alexis Borisy

Third Rock Ventures

Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation of new companies. He co-founded Foundation Medicine and served as the company's first CEO and currently as its Chairman, co-founded Blueprint Medicines, and launched and is serving as interim CEO of Warp Drive Bio. Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised more than $1b in financing and business development deals, and has authored numerous scientific papers and patents.

Mr. Borisy was honored as the Massachusetts Institute of Technology's Technology Review Innovator of the Year, was chosen as the New England Entrepreneur of the Year in Life Sciences, and was honored as a Presidential Scholar. Mr. Borisy's undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work at Harvard University.